NCT05125874View on ClinicalTrials.gov

Clinical Study for Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Immunization

NAUnknownINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

September 30, 2021

Primary Completion Date

August 30, 2023

Study Completion Date

September 30, 2023

Conditions
COVID-19 Pandemic
Interventions
BIOLOGICAL

Recombinant SARS-CoV-2 Fusion Protein Vaccine

The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.

Trial Locations (1)

519000

Zhuhai Peoples' Hospital Medical Group, Zhuhai

Sponsors
All Listed Sponsors
lead

Livzon Pharmaceutical Group Inc.

INDUSTRY